Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk has cut ties with Hims & Hers Health, alleging that the latter company has engaged in deceptive marketing ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

The breakup comes due to Novo Nordisk’s claims that Hims & Hers has ‘failed to adhere to the law’ by continuing to sell ...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. The breakup came after Novo raised concerns about Hims selling ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...